Market Overview

HeartWare Sees Q4 Sales ~$32M

Related HTWR
Benzinga's Top Upgrades
Bank Of America Upgrades HeartWare; Downgrades EndoChoice, Tandem

HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects total revenues for the fourth quarter of 2012 will be approximately $32 million, bringing expected full-year 2012 revenues to approximately $110 million.

Posted-In: News Guidance


Related Articles (HTWR)

View Comments and Join the Discussion!